Assessment, SelfNCT06260189
Assessment Of Serum And Tissue Levels Of Cold-Inducible RNA-Binding Protein In Patients With Lichen Planus
An observational study of Assessment, Self, run by Sohag University at 1 site in Egypt.
Trial summary
Lichen planus (LP) is a chronic inflammatory mucocutaneous disease of unknown etiology. Pathogenesis of LP is not completely understood, but it's considered a T-cell-mediated autoimmune disease. Read more about this study
- Who is it for?
- Ages 18 to 60 yearsHealthy volunteers can take part
- Conditions the study is for
- Assessment, Self
- How many people
- 80 participants
- Where
- 1 siteEgypt
- Study dates
- Feb 2024to Oct 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- Healthy volunteers accepted
- Adult
Study population: 40 patients with LP and 40 age and gender matched healthy controls who will attend the Dermatology Outpatient Clinics, Sohag University Hospitals. Diagnosis of LP will be clinically and will be confirmed by dermoscopy.
Who may be able to join
- Patients from both sexes aged 18 - 60 years, having clinical and dermoscopic confirmed LP and did not receive any topical or systemic treatment in the last 3 months for LP.
Who cannot join
- 1 . Pregnancy and lactation. 2. Patients with any infections or sepsis. 3. Patients with any other dermatological diseases associated with increased CIRP levels (eg. psoriasis, vitiligo or alopecia areata).
- 4. Patients with systemic illness (cardiac, renal, hepatic or respiratory), malignancy, with history of connective tissue diseases or on immunosuppressive treatment.
- 5. Patients who received any topical or systemic treatment for LP 3 months before the study.
- 6. Patients with oral, nail or scalp LP.
Trial locations and contacts
1 site in 1 country.
Egypt1 site, 1 recruiting
- Recruiting
Aya Ahmed Elsayed
Sohag, 82511
Aya A Elsayed, Msc, 00201060094631 ext. Egypt, aya_shando@yahoo.com
About this study
Lichen planus (LP) is a chronic inflammatory mucocutaneous disease of unknown etiology.
Pathogenesis of LP is not completely understood, but it's considered a T-cell-mediated autoimmune disease. Cold-inducible RNA binding protein (CIRP or CIRBP) is a member of the glycine-rich RNA-binding protein family, Recent studies proved that CIRP acts as a tumor promoter through its actions on different cellular proliferation levels, Recently, the role of the damage associated molecular proteins and cytokines was highlighted in the pathogenesis of many disorders including psoriasis, alopecia areata, vitiligo, rheumatoid arthritis, other autoimmune diseases as well as several types of cancer. The aim of this study is to compare serum and tissue levels of CIRP in patients with LP and healthy controls.
Read the detailed description
The aims of this study are:
- Assessment of serum and tissue levels of CIRP in patients with LP.
- To compare serum and tissue levels of CIRP in patients with LP and healthy controls.
- To compare CIRP levels according to LP severity. A cross-sectional study will be conducted on 40 patients with LP and 40 age and gender matched healthy controls. Diagnosis of LP will be clinically and will be confirmed by dermoscopy.
- Methods of the study:
- Evaluation of CIRP expression: Every participant in this study will be subjected to both blood sampling and skin biopsy taking in the same session, then each sample will be processed separately and blindly at the Clinical Pathology, and Histology Departments as following:
- Blood sampling:
Three ml venous blood sample will be taken from every one of the two studied groups in a free anticoagulant tube, enabling the blood to be coagulated. After 30 minutes of leaving the tube at room temperature till coagulation, then samples will be centrifuged (at 3000 rpm for 15 min) and the resultant serum will be stored at -80c until testing (22). Serum CIRP levels will be measured using an enzyme-linked immunosorbent assay analysis (ELISA) kit.
- Skin biopsies: One skin biopsy will be taken with 3 mm punch from each patient and control. These biopsies will be taken under local anesthesia from LP lesions and the same areas matched in control. All biopsies will be submitted to Histology Department, Sohag Faculty of Medicine. They will be fixed in 10% neutral buffered formalin, dehydrated in ascending grades of ethanol followed by immersion in xylene then impregnated in paraffin. Several 5 micron (5um) thick sections from each block will be taken. One slide will be stained by hematoxylin and eosin (H\&E) for routine histopathological examination. Other sections will be mounted on positive charged slides and stored at room temperature to be stained immunohistochemically.
- Histopathological assessment of H\&E-stained sections: Sections stained with H\&E will be evaluated under the light microscope to confirm the diagnosis of LP and to asses epidermal and dermal changes.
- Immunohistochemical (IHC) staining procedure The method used for immunostaining will be streptavidin-biotin amplified system. Paraffin-embedded tissue sections will be deparaffinized in xylene, rehydrated in a graded series of ethanol, and incubated with 3% hydrogen peroxide. Slides will be rinsed in phosphate - buffered saline (PBS) and then exposed to heat-induced epitope retrieval in citrate buffer solution (Ph 6) for 20 minutes. After cooling, the slides will be incubated over night at room temperature with mouse monoclonal anti-CIRP antibody (0.1 ml concentrated and diluted by PBS in a dilution 1:75). Detection of immunoreactivity will be carried out using the Universal Labeled Streptavidin-Biotin system, horseradish peroxidase. Finally, the reaction will be visualized by an appropriate substrate/ chromogen (diaminobenzidine) reagent. The staining procedure will include the negative controls obtained by substitution of primary antibodies with phosphate-buffered saline (16).
- Interpretation of CIRP immunostaining:
The CIRP immunostaining will be assessed separately and blindly in LP lesion and control cases. Epidermal and dermal cells will be assigned positive by the presence of brownish coloration detected by DAB reaction either in the cytoplasm or nuclei in ≥ 1 stained cells (25).
- Conditions
- Assessment, Self
- Keywords
- Lichen Planus, Cold-inducible RNA-binding protein
- Medical subject headings
- Lichen Planus
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Lichen Planus Cases | 40 cases with lichen planus from who skin biopsies and blood samples will be taken to assess cold inducible RNA binding protein levels in both tissues and serum. | |
| Healthy control group | 40 healthy controls from who skin biopsies and blood samples will be taken to assess serum and tissue levels of cold-inducible RNA binding protein and compare them to active cases. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Assessment of cold-inducible RNA binding protein levels in serum and tissue
Skin biopsies and blood samples will be taken to assess CIRBP levels
Measured: about one year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Feb 2024
- Study startFeb 2024 (estimated)
- Primary completionFeb 2025 (estimated)
- Study completionOct 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Assessment, SelfStudies of the same condition, open and under way.
- More trials run by Sohag UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Enrolment
- 80 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sohag University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Aya Ahmed Elsayed, Sohag University
- Investigators
- Mohammed A Abu El-Hamd, MD, Study chair, Sohag UniversitySoha H Aboeldahab, MD, Study director, Sohag UniversityRasha I Mohamed, MD, Study director, Sohag University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06260189
- Sponsor's protocol ID
- Soh-Med-24-01-02MD
- Status last verified
- Feb 2024
- First submitted
- 7 Feb 2024
- Last updated
- 15 Feb 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Feb 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Assessment Of Serum And Tissue Levels Of Cold-Inducible RNA-Binding Protein In Patients With Lichen Planus
- ClinicalTrials.gov ID
- NCT06260189
- Acronym / sponsor ID
- Soh-Med-24-01-02MD
- Conditions
- Assessment, Self
- Keywords
- Lichen Planus, Cold-inducible RNA-binding protein
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 80 participants (estimated)
- Lead sponsor
- Sohag UniversityUniversity, hospital or other
- Study start
- Feb 2024 (estimated)
- Primary completion
- Feb 2025 (estimated)
- Study completion
- Oct 2025 (estimated)
- First posted
- 15 Feb 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Lichen planus (LP) is a chronic inflammatory mucocutaneous disease of unknown etiology.
Pathogenesis of LP is not completely understood, but it's considered a T-cell-mediated autoimmune disease. Cold-inducible RNA binding protein (CIRP or CIRBP) is a member of the glycine-rich RNA-binding protein family, Recent studies proved that CIRP acts as a tumor promoter through its actions on different cellular proliferation levels, Recently, the role of the damage associated molecular proteins and cytokines was highlighted in the pathogenesis of many disorders including psoriasis, alopecia areata, vitiligo, rheumatoid arthritis, other autoimmune diseases as well as several types of cancer. The aim of this study is to compare serum and tissue levels of CIRP in patients with LP and healthy controls.
Detailed description
The aims of this study are:
- Assessment of serum and tissue levels of CIRP in patients with LP.
- To compare serum and tissue levels of CIRP in patients with LP and healthy controls.
- To compare CIRP levels according to LP severity. A cross-sectional study will be conducted on 40 patients with LP and 40 age and gender matched healthy controls. Diagnosis of LP will be clinically and will be confirmed by dermoscopy.
- Methods of the study:
- Evaluation of CIRP expression: Every participant in this study will be subjected to both blood sampling and skin biopsy taking in the same session, then each sample will be processed separately and blindly at the Clinical Pathology, and Histology Departments as following:
- Blood sampling:
Three ml venous blood sample will be taken from every one of the two studied groups in a free anticoagulant tube, enabling the blood to be coagulated. After 30 minutes of leaving the tube at room temperature till coagulation, then samples will be centrifuged (at 3000 rpm for 15 min) and the resultant serum will be stored at -80c until testing (22). Serum CIRP levels will be measured using an enzyme-linked immunosorbent assay analysis (ELISA) kit.
- Skin biopsies: One skin biopsy will be taken with 3 mm punch from each patient and control. These biopsies will be taken under local anesthesia from LP lesions and the same areas matched in control. All biopsies will be submitted to Histology Department, Sohag Faculty of Medicine. They will be fixed in 10% neutral buffered formalin, dehydrated in ascending grades of ethanol followed by immersion in xylene then impregnated in paraffin. Several 5 micron (5um) thick sections from each block will be taken. One slide will be stained by hematoxylin and eosin (H\&E) for routine histopathological examination. Other sections will be mounted on positive charged slides and stored at room temperature to be stained immunohistochemically.
- Histopathological assessment of H\&E-stained sections: Sections stained with H\&E will be evaluated under the light microscope to confirm the diagnosis of LP and to asses epidermal and dermal changes.
- Immunohistochemical (IHC) staining procedure The method used for immunostaining will be streptavidin-biotin amplified system. Paraffin-embedded tissue sections will be deparaffinized in xylene, rehydrated in a graded series of ethanol, and incubated with 3% hydrogen peroxide. Slides will be rinsed in phosphate - buffered saline (PBS) and then exposed to heat-induced epitope retrieval in citrate buffer solution (Ph 6) for 20 minutes. After cooling, the slides will be incubated over night at room temperature with mouse monoclonal anti-CIRP antibody (0.1 ml concentrated and diluted by PBS in a dilution 1:75). Detection of immunoreactivity will be carried out using the Universal Labeled Streptavidin-Biotin system, horseradish peroxidase. Finally, the reaction will be visualized by an appropriate substrate/ chromogen (diaminobenzidine) reagent. The staining procedure will include the negative controls obtained by substitution of primary antibodies with phosphate-buffered saline (16).
- Interpretation of CIRP immunostaining:
The CIRP immunostaining will be assessed separately and blindly in LP lesion and control cases. Epidermal and dermal cells will be assigned positive by the presence of brownish coloration detected by DAB reaction either in the cytoplasm or nuclei in ≥ 1 stained cells (25).
Study design
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Lichen Planus Cases | – | –40 cases with lichen planus from who skin biopsies and blood samples will be taken to assess cold inducible RNA binding protein levels in both tissues and serum. |
| Healthy control group | – | –40 healthy controls from who skin biopsies and blood samples will be taken to assess serum and tissue levels of cold-inducible RNA binding protein and compare them to active cases. |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- 40 patients with LP and 40 age and gender matched healthy controls who will attend the Dermatology Outpatient Clinics, Sohag University Hospitals. Diagnosis of LP will be clinically and will be confirmed by dermoscopy.
Key inclusion criteria (1 listed)
- Patients from both sexes aged 18 - 60 years, having clinical and dermoscopic confirmed LP and did not receive any topical or systemic treatment in the last 3 months for LP.
Key exclusion criteria (4 listed)
- 1 . Pregnancy and lactation. 2. Patients with any infections or sepsis. 3. Patients with any other dermatological diseases associated with increased CIRP levels (eg. psoriasis, vitiligo or alopecia areata).
- 4. Patients with systemic illness (cardiac, renal, hepatic or respiratory), malignancy, with history of connective tissue diseases or on immunosuppressive treatment.
- 5. Patients who received any topical or systemic treatment for LP 3 months before the study.
- 6. Patients with oral, nail or scalp LP.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Assessment of cold-inducible RNA binding protein levels in serum and tissue
Time frame: about one year
Skin biopsies and blood samples will be taken to assess CIRBP levels
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Feb 2024.
Related trials for Assessment, Self
Not yet recruiting
Preventive and Personalized Digital Emotion Regulation Skills Intervention to Reduce Depression and Anxiety in Youths With Adverse Childhood Experiences
Adverse Childhood Experience, Depression / Major Depressive Disorder
Not yet recruiting
AI Smart Glasses Feedback for Intubation Training in Medical Students
Intubation, Intratracheal, Medical Education
Not yet recruiting
Use and Acceptability of an AI-Assisted Health Application for Individuals Living With a Chronic Condition
Hypertension, Diabetes Mellitus, Type 2
Recruiting
Nutrition Outcomes Using a Randomized Intervention Via Smartphone on Dietary Habits
Healthy Adult Participants, Mindful Eating Intervention
Not yet recruiting
Study to Evaluate Xtressé Gummy Supplement in Women With Thinning Hair
Androgenetic Alopecia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Mohammed A Abu El-Hamd, MD study chair
Sohag University
Soha H Aboeldahab, MD study director
Sohag University
Rasha I Mohamed, MD study director
Sohag University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Assessment, Self, run by Sohag University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 15 Feb 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Aya A Elsayed, Msc (00201060094631 ext. Egypt, aya_shando@yahoo.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Assessment of cold-inducible RNA binding protein levels in serum and tissue (time frame: about one year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Feb 2024.